ARTICLE | Company News

G-BA: No additional benefit for Tecfidera in MS

November 22, 2014 2:24 AM UTC

Germany's Federal Joint Committee (G-BA) has concurred with the Institute for Quality and Efficiency in Healthcare (IQWiG) that Tecfidera dimethyl fumarate from Biogen Idec Inc. (NASDAQ:BIIB) offers no additional benefit over interferon beta-1a to treat relapsing-remitting multiple sclerosis (RRMS).

G-BA's final assessment was published Thursday, and mirrored the finding IQWiG reached in August (see BioCentury Extra, Aug. 4). ...